Some debates never die, they just take new forms.

Just when biotech and pharmaceutical companies thought the debate about FDA reform was over, pressure on the FDA to slow approvals threatens to reignite over a series of four drug withdrawals: Interneuron Pharmaceuticals Inc.'s Redux dexfenfluramine and Wyeth-Ayerst's Pondimin fenfluramine for obesity, Roche's Posicor for high blood pressure and now Wyeth-Ayerst's Duract non-steroidal anti-inflammatory drug for pain.